Elicera Therapeutics AB
The answer first
Does Elicera Therapeutics beat the market?
No, Elicera Therapeutics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 15% of Nordic stocks
- Quality67
- Value7
- Trend21
No. 149 of 195 in healthcare
Max for seven days
Follow Elicera Therapeutics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Elicera Therapeutics
Your first answer is free, no account needed.
Do you own Elicera Therapeutics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Elicera Therapeutics and a few more. Free, no card.
Super Stock+44.6%In short
- Elicera Therapeutics has fallen 53.6% over the past year, including dividends.
- Overall, Elicera Therapeutics ranks better than 15% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 90.0%. The price is 71.6% below its peak now.
What do analysts think of Elicera Therapeutics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 15% of Nordic stocks.
No. 149 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 92 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity–
- Asset turnoverSales divided by everything the company owns0.00
- Return on equityProfit divided by equity−32.0%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 153 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.2
- P/SPrice divided by salesnegative earnings
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 124 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−6.0%
- 6 months−18.8%
- 9 months−56.8%
- 12 months−53.6%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Elicera Therapeutics
One fund we follow owns Elicera Therapeutics. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Elicera Therapeutics
Elicera Therapeutics AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 3 employees.
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in late preclinical evaluation stage for the treatment of brain tumors.


See the full analysis of Elicera Therapeutics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card